YMTX vs. CPIX, NRBO, LUMO, APLM, SYBX, MEIP, KALA, AKTX, VBIV, and AYTU
Should you be buying Yumanity Therapeutics stock or one of its competitors? The main competitors of Yumanity Therapeutics include Cumberland Pharmaceuticals (CPIX), NeuroBo Pharmaceuticals (NRBO), Lumos Pharma (LUMO), Apollomics (APLM), Synlogic (SYBX), MEI Pharma (MEIP), KALA BIO (KALA), Akari Therapeutics (AKTX), VBI Vaccines (VBIV), and Aytu BioPharma (AYTU). These companies are all part of the "pharmaceutical preparations" industry.
Cumberland Pharmaceuticals (NASDAQ:CPIX) and Yumanity Therapeutics (NASDAQ:YMTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their community ranking, profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.
In the previous week, Yumanity Therapeutics had 1 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 1 mentions for Yumanity Therapeutics and 0 mentions for Cumberland Pharmaceuticals. Cumberland Pharmaceuticals' average media sentiment score of 0.67 beat Yumanity Therapeutics' score of 0.00 indicating that Yumanity Therapeutics is being referred to more favorably in the news media.
Cumberland Pharmaceuticals has a net margin of -21.67% compared to Cumberland Pharmaceuticals' net margin of -660.61%. Yumanity Therapeutics' return on equity of 0.21% beat Cumberland Pharmaceuticals' return on equity.
Cumberland Pharmaceuticals received 173 more outperform votes than Yumanity Therapeutics when rated by MarketBeat users. However, 70.00% of users gave Yumanity Therapeutics an outperform vote while only 44.74% of users gave Cumberland Pharmaceuticals an outperform vote.
Cumberland Pharmaceuticals has higher revenue and earnings than Yumanity Therapeutics. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Yumanity Therapeutics, indicating that it is currently the more affordable of the two stocks.
15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. Comparatively, 25.1% of Yumanity Therapeutics shares are owned by institutional investors. 43.3% of Cumberland Pharmaceuticals shares are owned by insiders. Comparatively, 12.5% of Yumanity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Cumberland Pharmaceuticals has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500. Comparatively, Yumanity Therapeutics has a beta of 0.32, meaning that its share price is 68% less volatile than the S&P 500.
Summary
Cumberland Pharmaceuticals beats Yumanity Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Yumanity Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for YMTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding YMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Yumanity Therapeutics Competitors List
Related Companies and Tools
